Back

Impact of surveillance colonoscopy on colorectal cancer incidence and mortality in Lynch syndrome - a national observational cohort study of patients in the English NHS 2010-2022

Huntley, C.; Loong, L.; Mallinson, C.; Rahman, T.; Torr, B.; Allen, S.; Allen, I.; Hassan, H.; Fru, Y. W. J.; Tataru, D.; Paley, L.; Vernon, S.; Houlston, R.; Muller, D.; Lalloo, F.; Shaw, A.; Burn, J.; Morris, E.; Tischkowitz, M.; Antoniou, A. C.; Pharoah, P. D. P.; Monahan, K.; Hardy, S.; Turnbull, C.

2026-04-22 oncology
10.64898/2026.04.16.26351020 medRxiv
Show abstract

BackgroundLynch syndrome (LS) is a cancer susceptibility syndrome caused by germline pathogenic variants in DNA mismatch repair (MMR) genes. Due to increased risk of colorectal cancer (CRC), enhanced colonoscopic surveillance is recommended for heterozygote MMR-carriers. ObjectiveUsing a registry of English LS patients linked to digital National Health Service records, we aimed to assess adherence of MMR-carriers to national surveillance guidelines, and to determine the impact of surveillance on CRC incidence and mortality. DesignWe described the frequency of colonoscopies in 4,732 MMR-carriers and used logistic regression to determine predictors of surveillance adherence. For MMR-carriers with a record of surveillance and those without, we: estimated age-specific annual CRC incidence rates (AS-AIRs) and cumulative lifetime risks, assessed for stage-shift by comparing CRC stage distributions and stage-specific AS-AIRs, and estimated risks of death from CRC and any cause using Kaplan-Meier methods and Cox Proportional Hazards regression. ResultsSurveillance at a mean interval of [≤] 3 years (n=3028) was associated with a decrease in CRC-specific and all-cause mortality, without an associated change in total CRC incidence, even after multivariate adjustment. No strong evidence of stage-shift was observed. Colonoscopic surveillance at a mean interval of [≤] 2 years (n=1569) was associated with an increase in total CRC incidence. Incidence of early-stage cancers was also higher, with no corresponding decrease in late-stage cancers, which may reflect the short follow-up period or the impact of overdiagnosis. ConclusionThe observed reduction in all-cause mortality amongst regularly-surveilled MMR-carriers may indicate an impact of surveillance on CRC-specific mortality, though in the context of a non-randomised study likely reflects the influence of selection bias. KEY MESSAGES OF ARTICLEO_ST_ABSWhat is already known on this topicC_ST_ABSRegular surveillance colonoscopy is recommended in Lynch syndrome, though evidence to support this remains mixed. We searched PubMed for articles published from inception to 01/05/2024 using the terms "Lynch syndrome", "HNPCC", "colonoscopy", "sigmoidoscopy", "surveillance", and "screening". We found one controlled trial and several small analytical studies dating from the early 2000s which compared surveilled and non-surveilled populations and found surveillance to be associated with reduced colorectal cancer (CRC) incidence and improved survival. More recent longitudinal observational studies, most without comparator groups, found a high incidence of CRC in LS populations despite being resident in countries where surveillance was recommended. A small number of studies directly assessed time since last colonoscopy against CRC incidence and stage with mixed findings. Finally, cross-sectional comparisons between countries of CRC incidence rates and surveillance interval recommendations found no relationship between the two1,2. What this study addsHere, we conduct an observational cohort study on a large national cohort of MMR germline pathogenic variant (GPV) carriers (MMR-carriers) in England (n=4,732), comparing CRC incidence and mortality in individuals with a record of regular surveillance to those without. Through linkage of the English National Lynch Syndrome Registry to Hospital Episodes Statistics data, we are uniquely able to study a comprehensive national population of MMR-carriers and identify the dates on which colonoscopies were undertaken over time, allowing assessment of adherence to national surveillance guidelines and the impact this has on CRC outcomes. Notably, receipt of regular colonoscopy was strongly associated with deprivation as well as ethnicity. The results show that regular surveillance at an average interval of 3 years (or less) is not associated with a reduction in CRC incidence when compared to less frequent surveillance, but an apparent decrease in both CRC-specific and overall mortality is observed, even after adjustment for confounding variables. Conversely, regular surveillance at an average interval of 2 years (or less) is associated with an increase in CRC incidence when compared to less frequent surveillance, which may suggest increased diagnosis of early-stage cancers or, due to the absence of a reduction in late-stage cancers, overdiagnosis. The observed impact of surveillance on overall mortality may demonstrate the impact of surveillance on CRC-specific mortality, or, in the context of an observational (non-randomised) study, indicate that the results are subject to selection bias. How this study might affect research, practice, or policyEvidence for the benefit of surveillance colonoscopy remains mixed. Whilst polypectomy would be anticipated to prevent CRC development (thus reducing CRC incidence), several studies have observed increased frequency of CRCs in MMR-carriers undergoing frequent surveillance colonoscopy, which may reflect overdiagnosis. The selection bias inherent to observational studies of surveillance renders mortality outcomes challenging to interpret. Randomised controlled trials of colonoscopic surveillance in MMR-carriers are required for effectiveness of this intervention to be accurately assessed. Given ethical and feasibility challenges, randomised controlled trials might be complemented by quasi-experimental designs using advanced observational methods for assessing effectiveness.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
British Journal of Cancer
42 papers in training set
Top 0.1%
17.3%
2
Gut
36 papers in training set
Top 0.1%
12.2%
3
Cancer Epidemiology, Biomarkers & Prevention
17 papers in training set
Top 0.1%
12.2%
4
Cancer Medicine
24 papers in training set
Top 0.2%
4.8%
5
International Journal of Cancer
42 papers in training set
Top 0.2%
4.8%
50% of probability mass above
6
PLOS ONE
4510 papers in training set
Top 37%
3.8%
7
BMJ Open
554 papers in training set
Top 6%
3.5%
8
BMC Medicine
163 papers in training set
Top 2%
3.5%
9
Gastroenterology
40 papers in training set
Top 0.7%
2.7%
10
JCO Precision Oncology
14 papers in training set
Top 0.1%
2.3%
11
Nature Communications
4913 papers in training set
Top 47%
2.0%
12
eClinicalMedicine
55 papers in training set
Top 0.5%
1.8%
13
BMC Cancer
52 papers in training set
Top 1%
1.7%
14
JAMA Network Open
127 papers in training set
Top 2%
1.7%
15
Annals of Oncology
13 papers in training set
Top 0.6%
1.5%
16
PLOS Medicine
98 papers in training set
Top 3%
1.5%
17
Scientific Reports
3102 papers in training set
Top 62%
1.5%
18
JNCI: Journal of the National Cancer Institute
16 papers in training set
Top 0.5%
1.2%
19
Frontiers in Oncology
95 papers in training set
Top 3%
1.2%
20
The Lancet Regional Health - Americas
22 papers in training set
Top 0.1%
1.2%
21
Journal of Clinical Medicine
91 papers in training set
Top 5%
0.9%
22
Journal of Medical Genetics
28 papers in training set
Top 0.4%
0.9%
23
PeerJ
261 papers in training set
Top 14%
0.8%
24
npj Precision Oncology
48 papers in training set
Top 1%
0.8%
25
European Journal of Human Genetics
49 papers in training set
Top 1%
0.8%
26
Cancers
200 papers in training set
Top 4%
0.8%
27
European Journal of Cancer
10 papers in training set
Top 0.6%
0.7%
28
American Journal of Gastroenterology
15 papers in training set
Top 0.3%
0.7%
29
EClinicalMedicine
21 papers in training set
Top 1%
0.7%
30
JNCI Cancer Spectrum
10 papers in training set
Top 0.6%
0.7%